<div id="readability-page-1"><div>Oct 30 (Reuters)-Ono Pharmaceutical Co LtdCONSOLIDATED FINANCIAL HIGHLIGHTS(in billions of yen unless specified)6 months ended 6 months ended Year toSep 30, 2025 Sep 30, 2024 Mar 31, 2026LATEST YEAR-AGO COMPANYRESULTS RESULT FORECASTSales 257.14 240.34 490.00(+7.0 pct) (-7.1 pct) (+0.6 pct)Operating 52.07 48.79 85.00(+6.7 pct) (-49.7 pct) (+42.3 pct)Pretax 52.18 47.54 85.00(+9.7 pct) (-52.1 pct) (+43.3 pct)Net 40.09 37.44 67.00(+7.1 pct) (-49.7 pct) (+33.9 pct)EPS Basic 85.33 yen 79.71 yen 142.62 yenEPS Diluted 85.28 yen 79.66 yenAnn Div 80.00 yen 80.00 yen-Q2 Div 40.00 yen 40.00 yen-Q4 Div 40.00 yen 40.00 yenNOTE - Ono Pharmaceutical Co Ltd.(Figures are reported based on international accounting rules (IFRS).)If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-halfdividend and Q4 to the second-half dividend announced before a new corporate law in2006 allowed companies to pay and report dividends on a quarterly basis.*Net - represents Net profit attributable to owners of the parent company.To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4528.T</div></div>

OPHLY

Ono Pharmaceutical Co Ltd reported its consolidated financial results for the six months ending September 30, 2025. Sales increased by 7.0% to ¥257.14 billion, while operating profit rose by 6.7% to ¥52.07 billion. Net profit also saw a 7.1% increase, reaching ¥40.09 billion. The company maintained its annual dividend at ¥80.00 per share. These figures are based on IFRS accounting standards.

TABLE-Ono Pharm 6-MTH group results (IFRS)